

# Andrea Angioi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1586441/publications.pdf>

Version: 2024-02-01

21  
papers

1,197  
citations

623734

14  
h-index

713466

21  
g-index

21  
all docs

21  
docs citations

21  
times ranked

1322  
citing authors

#	ARTICLE	IF	CITATIONS
1	Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments. <i>Kidney International</i> , 2014, 86, 828-836.	5.2	373
2	The MEST score provides earlier risk prediction in IgA nephropathy. <i>Kidney International</i> , 2016, 89, 167-175.	5.2	190
3	Rituximab or Cyclophosphamide in the Treatment of Membranous Nephropathy: The RI-CYCLO Randomized Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 972-982.	6.1	103
4	Diagnosis of complement alternative pathway disorders. <i>Kidney International</i> , 2016, 89, 278-288.	5.2	74
5	Is there long-term value of pathology scoring in immunoglobulin A nephropathy? A validation study of the Oxford Classification for IgA Nephropathy (VALIGA) update. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1002-1009.	0.7	66
6	Complement activation in pauci-immune necrotizing and crescentic glomerulonephritis: results of a proteomic analysis. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, i139-i145.	0.7	59
7	Development and testing of an artificial intelligence tool for predicting end-stage kidney disease in patients with immunoglobulin A nephropathy. <i>Kidney International</i> , 2021, 99, 1179-1188.	5.2	47
8	Reproducibility of the Oxford classification of immunoglobulin A nephropathy, impact of biopsy scoring on treatment allocation and clinical relevance of disagreements: evidence from the VALidation of IGA study cohort. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1681-1690.	0.7	44
9	Clinicopathologic predictors of renal outcomes in light chain cast nephropathy: a multicenter retrospective study. <i>Blood</i> , 2020, 135, 1833-1846.	1.4	42
10	Improving treatment decisions using personalized risk assessment from the International IgA Nephropathy Prediction Tool. <i>Kidney International</i> , 2020, 98, 1009-1019.	5.2	35
11	Quantifying Duration of Proteinuria Remission and Association with Clinical Outcome in IgA Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 436-447.	6.1	34
12	Metformin associated lactic acidosis: a case series of 28 patients treated with sustained low-efficiency dialysis (SLED) and long-term follow-up. <i>BMC Nephrology</i> , 2018, 19, 77.	1.8	26
13	Bortezomib-induced acute interstitial nephritis. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 1225-1229.	0.7	25
14	Recurrent Light Chain Proximal Tubulopathy in a Kidney Allograft. <i>American Journal of Kidney Diseases</i> , 2016, 68, 483-487.	1.9	14
15	Treatment of primary membranous nephropathy: where are we now?. <i>Journal of Nephrology</i> , 2018, 31, 489-502.	2.0	14
16	Chronic Kidney Disease of Undetermined Etiology around the World. <i>Kidney and Blood Pressure Research</i> , 2021, 46, 142-151.	2.0	12
17	Temporal IgG Subtype Changes in Recurrent Idiopathic Membranous Nephropathy. <i>American Journal of Transplantation</i> , 2016, 16, 2964-2972.	4.7	10
18	FSGS: from pathogenesis to the histological lesion. <i>Journal of Nephrology</i> , 2016, 29, 517-523.	2.0	9

#	ARTICLE	IF	CITATIONS
19	Renal hemodynamic effects of the HMG-CoA reductase inhibitors in autosomal dominant polycystic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1290-1295.	0.7	9
20	Familial antglomerular basement membrane disease in zero human leukocyte antigen mismatch siblings. <i>Clinical Nephrology</i> , 2017, 88, 277-283.	0.7	7
21	Extensive proximal tubular necrosis without recovery following the ingestion of <i>Amanita phalloides</i> : a case report. <i>Journal of Nephrology</i> , 2021, 34, 2137-2140.	2.0	4